ALLERGY THERAPEUTICS PLC

AGM Information • Jul 31, 2023

National Storage Mechanism | Additional information

RNS Number : 7738H

Allergy Therapeutics PLC

31 July 2023

Allergy Therapeutics plc

("Allergy Therapeutics", the "Company" or the "Group")

Result of General Meeting

31 July 2023: Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that at the General Meeting today, held for the purposes of approving the Company's annual report and accounts for the year ended 30 June 2022 (the "2022 Accounts"), all resolutions were duly passed.

All resolutions were voted on by way of a poll. The results of the poll were as follows:

Resolution	Votes For	% of votes for	Votes Against	% of votes against	Votes Withheld	Total votes cast
1. To receive the Directors' report, the consolidated financial statements and the auditors' report of the Company for the year ended 30 June 2022 (the "2022 Accounts")	332,831,805	99.75%	822,693	0.25%	97,047	333,751,545
2. To approve the Directors' remuneration report, as set out on pages 64 to 72 of the 2022 Accounts	330,801,478	99.27%	2,443,679	0.73%	506,388	333,751,545

- ENDS -

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

+44 (0)1903 845 820

Panmure Gordon (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

Consilium Strategic Communications

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMXFLFXXDLXBBF